ImmuneRegen BioSciences Responds to Department of Health and Human Services Request for Information for Medical Countermeasures

SCOTTSDALE, Ariz., Dec. 11  /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC:IRBO) (BULLETIN BOARD: IRBO) , today announced that it has responded to a Request for Information (RFI), issued by the Department of Health and Human Services (DHHS), for medical countermeasures to address chemical, biological, radiological and nuclear (CBRN) threats.  This response was initiated on October 31, 2006 in accordance with the guidelines set forth in the RFI request.

ImmuneRegen's response to the RFI will address the DHHS's interest in medical countermeasures that could be readily deployed and used in preparation for, or response to, a CBRN event.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM).  Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator.  Radilex(TM) is the trade name used in referring to formulations of Homspera for potential indications for the possible treatment of the effects of exposure to ionizing radiation. Viprovex(TM) is the trade name used in referring to formulations of Homspera for potential indications for the possible treatment of the effects of viral and bacterial infections.  Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P.  Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.  All of the Company's research and development efforts are early, pre-clinical stage and Homspera, as Viprovex(TM) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.  For more information, please visit the company's website at http://www.immuneregen.com/.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995.  The Company intends that such forward-looking statements be subject to the safe harbors created thereby.  These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties.  The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended September 30, 2006 and on Form 10-KSB for the twelve months ended December 31, 2005 as filed with the Securities and Exchange Commission.  There are no guarantees that any of the Company's proposed products will prove to be commercially successful.  The Company undertakes no duty to update forward-looking statements.

  Contact:

    Investor relations:  Tony Schor or Lindsay Kenoe
    Investor Awareness, Inc.
    847-945-2222
    http://www.investorawareness.com/

    MEDIA CONTACT: W. Jason Grimley
    Spelling Communications
    310-477-9500
    

DATASOURCE: ImmuneRegen BioSciences, Inc.



CONTACT:  Investor relations, Tony Schor or Lindsay Kenoe, both of

Investor Awareness, Inc., [phone], for ImmuneRegen BioSciences, Inc.;

or Media, W. Jason Grimley of Spelling Communications, [phone],

, for ImmuneRegen BioSciences, Inc.



Web site:  http://www.immuneregen.com/ 

Copyright